Arrowhead Research's Nanotherapy Bet

Arrowhead is using a new nano sized approach to targeting and destroying disease.

Jan 7, 2014 at 11:35AM

Arrowhead Research (NASDAQ:ARWR) is using technology from Alnylam (NASDAQ:ALNY) and Isis (NASDAQ:IONS) to create gene interfering drugs targeting kidney disease and cancer. 

Two of the largest drugmakers, Roche (NASDAQOTH:RHHBY) and Shire (NASDAQ:SHPG), found Arrowhead's technology intriguing enough to ink contracts with the company to co-develop new therapies. Commercializing drugs from these relationships is still years away, but support from these two big players suggests Arrowhead is a company worth watching.  

Knock, knock. Nano-delivery is here
Arrowhead thinks nano sized delivery men can improve the ability of antisense technology to turn off genes associated with disease.

The company is combining Alnylam and Isis technology with nano structures designed to mimic how viruses invade cells. By building these dynamic polyconjugates, or DPCs, Arrowhead thinks it can more effectively deliver drug payloads to specific compartments within targeted cells.

It's an intriguing approach that addresses the problem of polypharmacology, or the unplanned interaction of drugs with unplanned targets. Such unplanned interaction, and the side effects like toxicity it causes, is a common reason drugs fail in human trials.  

Advancing into human trials
In 2011, Roche (NASDAQOTH:RHHBY) found Arrowhead's technology so promising that it agreed to hand over its RNA intellectual property, including licenses it held with Isis, in exchange for nearly 10% ownership. That deal gives Roche the opportunity to license and receive royalties on future Arrowhead drugs and provides Arrowhead with a well-heeled collaborator and part-owner.

Arrowhead will leverage that relationship this year as it advances its pre-clinical compounds, including ARC-520 for chronic hepatitis B, through human trials

During pre-clinical studies, ARC-520 showed promise as a treatment for kidney disease in primates. A chronically infected chimpanzee with the hep B virus treated ARC-520 saw a rapid reduction of 90% to 95% in HBV DNA, e-antigen, and s-antigen that didn't return to baseline until day 43, 43, and 71 respectively.

That gave Arrowhead and Roche enough confidence to move the drug into a small phase 1 trial in October. Safety data from that trial, which is studying the drug in patients with chronic HBV, was reported in December. Adverse events and severity were the same between placebo and ARC-520, with 75% of both treated and placebo subjects reporting mild or moderate adverse events. That safety profile is strong enough that Arrowhead and Roche will move the study into a phase 2a study to determine efficacy.

But Roche isn't the only one betting that Arrowhead's approach could work. Shire is working with the company to develop DPCs to deliver Shire's drugs. Shire will pay Arrowhead up to $32.8 million for each development candidate, as well as royalties.

Arrowhead is also working with Cerulean Pharma on CRLX-101, or camptothecinan, an anti-cancer compound originally discovered in the 1960s but deemed too toxic to advance through clinic. The two companies believe marrying camptothecinan with Arrowhead's nano targeting technology can overcome those safety concerns. They've completed enrollment for a phase 2 trial in non-small-cell lung cancer and Arrowhead stands to receive both milestone payments and royalties on net sales if the drug ever makes it to market. 

Alynylam is also licensing Arrowhead DPC technology for an undisclosed RNAi therapy as part of its 5x15 pipeline goal to have five compounds in clinic by 2015. Under that agreement with Alynylam, Arrowhead will get both milestone and royalty payments if the therapy is ever commercialized.

Fool-worthy final thoughts
We may be miles away from having enough data to consider Arrowhead anything more than speculative.  But there are reasons to pay attention to the company and its progress.

ARC-520 may eventually help address a significant unmet need in hepatitis B given the disease can cause liver failure and liver cancer. That's potentially a big market given some 500,000 to 1 million of the 350 million people diagnosed with hepatitis B die every year from the disease. A payday could also come to Arrowhead shareholders thanks to collaborations with Shire and Alnylam.

However, Arrowhead remains an early stage company that offers more promise than proven results. That makes it suitable only for the most risk tolerant investor. As a result, investors may want to wait for mid-stage trial data on ARC-520 or CRLX-101 before jumping in.

Another intriguing stock to watch in 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC.  E.B. Capital's clients may or may not have positions in the companies mentioned.  Todd also owns Gundalow Advisor's, LLC.  Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Alnylam Pharmaceuticals and Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers